ClinicalTrials.gg
RecruitingNCT06223256Updated Mar 18, 2024

A Study of NBL-028 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of NBL-028 in Advanced Solid Tumor, sponsored by NovaRock Biotherapeutics, Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by NovaRock Biotherapeutics, Ltd (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
270
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, single agent study conducted in patients with advanced solid tumor types known to express Claudin 6 (CLDN6) for whom standard of care therapies are not available, are no longer effective, or not tolerated. This study consists two stages: dose-escalating and dose-expansion.

Dose escalation will be guided by the Bayesian optimal interval (BOIN) design including accelerated titration to determine the maximum tolerated dose (MTD) of NBL-028. Dose expansion - Additional patients (no more than 200) will be enrolled at the recommended dose or multiple doses (if necessary) determined in the dose escalation stage. Sponsor may elect to enroll specific tumor types into four cohorts.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

NovaRock Biotherapeutics, Ltd is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years old, should have fully understood the study and voluntarily signed an form.
  2. Patients with diagnosed advanced solid tumors with positive expression of CLDN6. Stage I: Patients have failed or cannot tolerate standard of care, or without standard treatment; Stage Ⅱ: Previously treated advanced solid tumors.
  3. Be able to provide previously well-preserved tumor tissue sections, or agree to undergo tumor tissue for central laboratory biomarker testing.
  4. At least one measurable target lesion according to 1.1.
  5. performance status of 0 or 1 at screening.
  6. ≥3 months.
  7. Adequate organ function within 7 days prior to the first dose defined as: (ANC) ≥1.5×10\^9/L; count (PLT) ≥100×10\^9/L;. (HGB) ≥90 g/L; Serum creatinine ≤ 1.5 × or Calculated (CrCl) (Cockcroft-Gault formula) ≥50 mL/min; Total (TBIL) ≤1.5×ULN (≤3×ULN when patients with Gilbert's disease); (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN if liver involvement is known).
  8. Serum pregnancy test for women of (WOCBP) is negative within 7 days prior to the first dose of the drug. The patient and his/her spouse must agree to use adequate from signing of informed consent form (ICF) to 3 months after the last dose, during which women should be non-lactating and men should refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  1. Previously received CLDN6-targeted or CD137-targeted treatment.
  2. Known uncontrolled central nervous system (CNS) cancer including , meningeal , or spinal cord compression.
  3. Patients with high risk of bleeding due to tumor invasion of important arteries.
  4. Has uncontrolled serous cavity effusion (such as pleural effusion, abdominal effusion, or pericardial effusion, etc) requiring repeated drainage.
  5. Has adverse events due to previous anti-tumor treatments that have not yet recovered to ≤Grade 1 according to v5.0;
  6. Developed immune-related adverse events (irAE) of grade ≥3 (CTCAE 5.0) with prior immunotherapy
  7. Known to exist any other malignant tumor requiring intervention.
  8. Have received anti-tumor treatments (such as chemotherapy, targeted therapy, biological therapy, etc.) or any other drugs or treatments within 4 weeks or 5 half-lives, whichever is shorter.
  9. Have received a live viral vaccine within 4 weeks before the first dose of study drug.
  10. Have received medications within 2 weeks prior to the first dose of study drug.
  11. Have active or serious bacterial, fungal, or viral infection requiring systemic anti-infective treatment within 2 weeks prior to the first dose of study drug.
  12. Have received radiation therapy or other localized palliative treatment within 2 weeks before the first dose of study drug.
  13. Have undergone major surgery within 4 weeks before the first dose of study drug, or scheduled to have major surgery during the study.
  14. Have a history of serious cardiovascular disease.
  15. Have active or history of diseases.
  16. A history of immunodeficiency, including testing positive, or having other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation.
  17. Active ; infection; syphilis infection, active tuberculosis.
  18. Hypersensitive to humanized monoclonal antibody products.
  19. Women during lactation or pregnancy.
  20. Any male and female patients with fertility who refuse to use effective methods throughout the entire trial period and within six months after the last administration.
  21. Other conditions that, in the opinion of the investigator, may affect the safety or compliance of drug treatment in this study, including but not limited to: psychiatric disorders, any severe or uncontrollable diseases, etc.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    NBL-028

    Patients will be treated with NBL-028 at starting dose of 0.01 mg/kg in dose escalation stage. In dose expansion stage, patients will be treated with NBL-028 at the recommended dose or multiple doses (if necessary) determined in the dose escalation stage.

    Drug: NBL-028

Interventions

  • DrugNBL-028

    Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT)

    Dose-limiting toxicity

    Time frame: Up to approximately 1 years

  2. Incidence and severity of adverse events (AE) and serious adverse events (SAE) Incidence, nature, and severity of adverse events will be graded according to the NCI CTCAE v5.0

    adverse events (AEs) and severe adverse events (SAEs)

    Time frame: Up to approximately 3 years

  3. Maximum Tolerated Dose(MTD) of NBL-028

    Maximum Tolerated Dose

    Time frame: Up to approximately 1 years

  4. Recommended Phase 2 dose(RP2D)

    Recommended Phase 2 dose

    Time frame: Up to approximately 1 years

Secondary outcomes

  1. Overall response rate (ORR).Determined using RECIST v1.1 criteria.

    Objective response rate

    Time frame: Up to approximately 3 years

  2. Pharmacokinetic (PK) profile of YBL-006.Assessed by parameter Cmax.

    Observed maximum concentration

    Time frame: Up to approximately 3 years

  3. Pharmacokinetic (PK) profile of YBL-006.Assessed by parameter Area under curve(AUC).

    AUC0-t

    Time frame: Up to approximately 3 years

  4. Pharmacokinetic (PK) profile of YBL-006.Assessed by parameter Tmax.

    Time to maximum concentration

    Time frame: Up to approximately 3 years

  5. Pharmacokinetic (PK) profile of YBL-006.Assessed by parameter t1/2.

    Apparent terminal Half-Life

    Time frame: Up to approximately 3 years

  6. anti-drug antibody(ADA)

    anti-drug antibody titer

    Time frame: Up to approximately 3 years

  7. Disease control rate(DCR)

    Disease control rate

    Time frame: Up to approximately 3 years

  8. Duration of response (DoR)

    Duration of response

    Time frame: Up to approximately 3 years

  9. Progression free survival(PFS)

    Progression free survival

    Time frame: Up to approximately 3 years

07

Study locations

1 of 1 sites recruiting
  • No.896 East Zhongshan Road, Shijiazhuang, Hebei Province, China.
    Shijiazhuang, Hebei, China
    Recruiting
    • Clinical Trials Information Group · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Jan 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 25, 2024
StartActual
Mar 8, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06223256
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Mar 8, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Mar 18, 2024

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587
Ruihua Xu, Ph.D
principal investigator · Sun Yat-Sen University (SYSU) Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion